Animal models of systemic sclerosis: prospects and limitations. - Test2 - elhamkhani - TriplyDB

Animal models of systemic sclerosis: prospects and limitations.

Animal models of systemic sclerosis: prospects and limitations.

http://www.wikidata.org/entity/Q37771308

about

The immune pathogenesis of scleroderma: context is everything Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis Molecular targets for therapy in systemic sclerosis Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.Tie2 as a novel key factor of microangiopathy in systemic sclerosis.Surgical approaches to create murine models of human wound healing Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis.Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.PDGF-BB Promotes Type I IFN-Dependent Vascular Alterations and Monocyte Recruitment in a Model of Dermal Fibrosis.The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis Protective role for miR-9-5p in the fibrogenic transformation of human dermal fibroblasts.OX40L blockade protects against inflammation-driven fibrosis.Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.Targeted therapies for systemic sclerosis.Animal models of scleroderma: current state and recent development.Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features.Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.Diagnosis and Management of Systemic Sclerosis: A Practical Approach.Recent advances in animal models of systemic sclerosis.Myeloid Populations in Systemic Autoimmune Diseases.A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice.Histone Demethylation and Toll-like Receptor 8-Dependent Cross-Talk in Monocytes Promotes Transdifferentiation of Fibroblasts in Systemic Sclerosis Via Fra-2.Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis.Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis.Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling.Female Reproductive System and Immunology.Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.Editorial: Bench to Bedside-and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe.Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies.

P2860

Q24633658-26F146C2-6DAB-4B54-8A0B-460A7B8743B6 Q26827629-28A63D1C-382F-460D-9B3A-2BA4529848BE Q28388130-B2FDEA64-0BFD-4E44-B8D2-FFE77CCCC6D1 Q28484123-672BEA10-5872-4737-B7AA-890DEFE32EBB Q33603627-F8C45130-3BB4-43F0-8C12-ADA2E9E4438C Q33730294-35862877-411A-4DAB-896D-E2AFC86CC5E1 Q34373111-422286D9-CAD5-40A8-AB75-1E62B26C0BE3 Q34452035-0E881B3D-BE38-4D13-B90B-D740F70BC916 Q35710188-F1899BF3-2175-4962-B845-5E1A11B775B4 Q35863725-3A676743-15C9-4FB3-AC2F-13DC6959F854 Q36010507-0AED32BA-3344-4316-A0EB-515EA487A959 Q36130126-9F1EBB4E-49A9-49F7-9BC0-23BB75B4FAFD Q36591533-2CC12C7E-290F-4085-BBC0-7C3AEF61B587 Q36633452-CF56F9AA-943A-43E0-BD58-B668C1AAA327 Q36965488-8C44D9BF-BE16-4506-A303-6FAD93474FBF Q37086713-D6052AE2-53B8-49D2-B87A-EA85C2D10173 Q37471585-C8173D3E-096E-415C-8EA5-9F687F14FFF2 Q37634132-4CD4FA88-A55D-4F63-B895-903D18154781 Q38097276-D02E4E5D-E01D-464B-B3A7-74FBC32FF679 Q38154834-282FBF1B-8A34-4545-9D37-47D4A2DBBCFF Q38489606-C54241EB-E3BB-403C-A1BB-B754D9AA753B Q38636049-E4A73C32-07E8-4677-8887-06384364C1A0 Q38667111-01A5B95F-16F9-459B-87E6-DE406F5C53C2 Q38701983-0AB8C53D-02D6-40B5-96C3-5630FC106C1E Q38772739-27BB15A1-29F4-4A71-81D5-09BFCCB8B7BD Q40047502-F8650226-F588-4612-872B-2D74919A8982 Q40057489-7D5EC042-255A-4FD8-843E-85C6FB4A99CE Q41095169-0072A203-006E-4281-AEEF-B6676654ED6C Q41147581-E4E9821A-498E-40EB-8EEA-E2CA98E017B7 Q41980258-603039DE-1BB7-4158-84D0-E4B36B30ED0E Q42416370-17AE2BC8-75C5-4D8F-B580-715E4F166063 Q42638573-D3EACC25-E3E9-4C3A-B7AA-B5610285C332 Q45207632-A56F9359-3D8C-47D1-B8AD-41C9949EEBA3 Q45971063-6348F628-2951-42AC-BBE7-C0DA07CC97AF Q46121852-B7D432B7-924C-48F5-8B4D-DEEAE27EDDA1 Q47619318-9C3B0A49-402A-4A3D-A27F-29ADDE066C98 Q48945028-89C3120C-1EC6-4D60-BC33-05FF02AD5197 Q50050279-2587E311-7F6F-41CD-A836-97EC187407FB Q50091398-9249AC32-9A10-4BF6-9344-AA522587CC1D Q50243147-3B631757-72AF-4CAF-B834-E6EDA801B4DA

P2860

Animal models of systemic sclerosis: prospects and limitations.

http://www.wikidata.org/entity/Q37771308

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Animal models of systemic sclerosis: prospects and limitations.

@en

Animal models of systemic sclerosis: prospects and limitations.

@nl

type

label

Animal models of systemic sclerosis: prospects and limitations.

@en

Animal models of systemic sclerosis: prospects and limitations.

@nl

prefLabel

Animal models of systemic sclerosis: prospects and limitations.

@en

Animal models of systemic sclerosis: prospects and limitations.

@nl

P1433

Q37771308-AC2E5E9A-0C1F-4B98-8A25-86B0C04109C6

P1476

Q37771308-3B0531F1-7AEF-4888-B5B3-418D56CCD922

P2093

Q37771308-791B4D10-BB52-408F-B355-4513DE9C45AE

Q37771308-858F3941-F537-426E-9A23-BD3DCE00E35F

Q37771308-EC7A44F9-1953-4C94-BF26-A2FEB72B4D94

P2860

Q37771308-3060BCC4-44E3-464E-873A-7EDCCBA5DEF7

Q37771308-306CEA83-7433-4691-994D-7A230C9D5544

Q37771308-A03428ED-87F0-4896-A8C0-5F12812F05A7

Q37771308-AF258C28-B2A2-412D-8478-6037D33E6FB9

Q37771308-D5DC9F4E-4DE7-4FA5-9B2F-9F96FADFDC82

Q37771308-F3EEA61E-52E4-4D2D-8000-753AA6B71D2E

P304

Q37771308-F3821FBF-46F6-43CE-9B7D-5FEF1F911EC3

P31

Q37771308-0C268C88-4C18-4657-AC08-890FF29497E3

P356

Q37771308-E7C9970F-78E7-496C-9EA8-B6313741C581

P433

Q37771308-3A73FC0B-A0AE-4154-B5C1-F9C3F6CF5B66

P478

Q37771308-293B2099-07DD-4255-A1DA-04939FFD5202

P50

Q37771308-718E2D46-74EC-4C02-A0CA-E628C2BC6586

P577

Q37771308-4395E0C6-8546-42E8-B40B-292EF1FD5F45

P5875

Q37771308-1168D882-0654-46CB-B3FF-A9363FF47116

P698

Q37771308-B255373D-3C53-48BD-8E2A-33F38EAF13E4

P356

P1433

Arthritis & Rheumatology

P1476

Animal models of systemic sclerosis: prospects and limitations.

@en

P2093

Christian Beyer

http://www.w3.org/2001/XMLSchema#string

Jörg H W Distler

http://www.w3.org/2001/XMLSchema#string

Oliver Distler

http://www.w3.org/2001/XMLSchema#string

P2860

Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis

Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli

Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome.

CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse

Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease.

Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma.

P304

2831-2844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.27647

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45115031

http://www.w3.org/2001/XMLSchema#string

P698

20617524

http://www.w3.org/2001/XMLSchema#string